Immunohistochemistry in diagnostic surgical pathology: Contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 2, 2010, Pages 169-176

  Idikio, Halliday A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Evidence based methods; Immunoperoxidase; Normalization; Protein lifecycle; Proteomics; Surgical pathology

Indexed keywords

ANTIBODY; FORMALDEHYDE; PARAFFIN; PROTEIN; TUMOR MARKER;

EVIDENCE BASED MEDICINE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; REVIEW; TISSUE FIXATION;

ANTIBODIES; EVIDENCE-BASED MEDICINE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PARAFFIN EMBEDDING; PATHOLOGY, SURGICAL; PROTEINS; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77951640280     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Robinson G, Dawson I. Immunochemical studies of the endocrine cells of the gastrointestinal tract II An immunoperoxidase technique for the localization of secretin-containing cells in human duodenum. J Clin Patho 1975; 28: 631-635.
2. Nakane P, Pierce G. Enzyme-labeled antibodies; preparation and application for the localization of antigens. J Histochem and Cytochem 1966; 14: 929-931.
3. Hanahan D, Weinberg R. The Hallmarks of Cancer. Cell 2000; 100:57-70.
4. Lewin B. Protein Synthesis. In: GENES VIII. Upper Saddle River, NJ 07458: Pearson/Prentice Hall; 2004. p. 135-166.
5. Krappmann D, Scheidereit C. A pervasive role of ubiquitin conjugation in activation and termination of IkB kinase pathways. EMBO Reports 2005;6(4):321-326.
6. Seet B, Dikic I, Zhou M-M, Pawson T. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006;7:473-483.
7. Wilson VG, Rosas-Acosta G. Wrestling with SUMO in a New Arena. Science STKE 2005(pe32).
8. Baek D, Villen J, Shin C, Camargo F, Gygi S, Bartel D. The impact of microRNAs on protein output. Nature 2008.
9. Hunter T. The Age of Crosstalk: Phosphorylation, Ubiquitination, and Beyond. Molecular Cell 2007; 28:730-738.
10. Peri J, Navarro J, Amanchy R, Kristiasen T, Jonnalagada C, Surendranath Vea. Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans. Genome Res 2003; 13:2363-2371.
11. Mandell J. Phosphorylation State-Specific Antibodies Applications in Investigative and Diagnostic Pathology. Am J Pathol 2003; 163:1687-1698.
12. Lim Y. Mining the Tumor Phosphoproteome for Cancer Markers. Clin Cancer Res 2005; 11(9):3163-3169.
13. Baker A, Dragovich T, Ihle N, Williams R, Fenoglio-Preiser C, Powls G. Stability of Phosphoprotein as a Biological Marker of Tumor Signaling. Clin Cancer Res 2005; 11(12):4338-4340.
14. Jin S, Levine A. The p53 functional circuit. Journal of Cell Science 2001;114:4139-4140.
15. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003; 116:4077-4085.
16. Wei C-L, Wu Q, Vega V, Chiu K, Ng P, Zhang T, et al. A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell 2006; 124:207-219.
17. Bode A, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
18. Bourdon J-C, Fernandes K, Murray-Zmijeweski F, Liu G, Diot A, Xirodimas D, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19:2122-2137.
19. Vousden K, Prives C. P53 and Prognosis: New Insights and Further Complexity. Cell 2005;120:7-10.
20. Schmitt C, Fridman J, Yang M, Baranov E, Hoffman R. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-298.
21. Trigiante G, Lu X. ASPPs and cancer. Nat Rev Cancer 2006;6:217-226.
22. Petricoin E, Zoon K, Kohn E, Liotta L. Clinical Proteomics: Translating Benchside Promise Into Bedside Reality. Nat Rev Drug Discov 2002;1:683-695.
23. Celis J, Gromov P, Gromova I, Moreira J, Cabezon T, Ambartsumian Nea. Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. Mol Cell Proteomics 2003;2:369-377.
24. Graham D, Elliott S, Van Eyk J. Broad -based proteomic strategies: a practical guide to proteomics and functional screening. J Physiol 2004;563(1):1-9.
25. Sanchez-Carbayo M, Socci N, Lozano J, Haab B, Cordon-Cardo C. Profiling Bladder Cancer Using Targeted Antibody Microarrays. Am J Pathol 2006;168:93-103.
26. Ludwig J, Weinstein J. Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat Rev Cancer 2005;5:845-856.
27. Dalton W, Friend S. Cancer Biomarkers An Invitation to the Table. Science 2006;312: 1165-1168.
28. Natkunam Y, Mason D. Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? Lab Invest 2006; 86:742-747.
29. Weil R. Incorporating Molecular Tools into Early-Stage Clinical Trials. PLos Med 2008; 5:e21.
30. Hawkins R. The Evidence Based Medicine Approach to Diagnostic Testing: practicalities and limitations. Clinical Biochem Review 2005; 26(May):7-18.
31. McQueen M. Overview of Evidence -based Medicine: Challenges for Evidence-based Laboratory Medicine. Clin Chem 2001; 47(8):1536-1546.
32. Mallet S, Deeks J, Halligan S, Hopewell S, Cornelius V, Altman D. Systematic reviews of diagnostic tests in cancer: review of methods and reporting. BMJ 2006; 333:413.
33. Ordonez N. The diagnostic utility of immunohistochemistry in distinguishing between epitheloid mesotheliomas and squamous cell carcinomas of the lung: a comparative study. Mod Pathol 2006; 19:417-429.
34. Evangelou E, Kyzas P, Trikalinos T. Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 2005;18(11):1490-1497.
35. Dennis J, Hvidsen T, Wit E, Komorowski J, Bell A, Downie I, et al. Markers of Adenocarcinoma Characteristic of the site of Origin: Development of a Diagnostic Algorithm. Clin Cancer Res 2005; 11(10):3766-3772.
36. Bast R, Lilja H, Urban N, Rimm D, Fritsche H, Gray J, et al. Translational Crossroads for Biomarkers. Clin Cancer Res 2005; 11(17):6103-6108.
37. Rimm D. What brown cannot do for you. Nat Biotechnol 2006; 24(8):914-916.
38. Cheang M, Treaba D, Speers C, Olivoto I, Badjik C, Chia S, et al. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol 2006; 24(36):5637-5644.
39. True L, Feng Z. Immunohistochemical Validation of Expression Microarray Results. J Mol Diagn 2005;7(2):149-151.
40. McCabe A, Dolled-Filhart M, Camp R, Rimm D. Automated Quantitative Analysis (AQUA) of In situ Protein Expression, Antibody Concentration, and Prognosis. J Natl Cancer Inst 2005; 97:1808-1815.
41. Betensky R, Nutt C, Batchelor T, Louis D. Statistical Considerations for Immunohistochemical Panel Development after Gene Expression Profiling of Human Cancers. J Mol Diagn 2005; 7(2):276-282.
42. Jones R, Gordus A, Krail J, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006; 439:168-174.
43. Norris A, Kahn C. Analysis of gene expression in pathophysiological states: Balancing false discovery and false negative rates. Proc Natl Acad Sci U S A 2006; 103:649-653.
44. Simon R. Development and Validation of Therapeutically Relevant Multi-Gene Biomarker Classifiers. JNCI 2005; 97(12):866-867.
45. Simon R, Radmacher M, Dobbin K, McShane L. Pitfalls in the Use of DNA Microarray Data for Diagnostic and Prognostic Classification. JNCI 2003; 95(1):14-18.
46. Tinker A, Boussioutas A, Bowtell D. The challenge of gene expression microarrays for the study of human cancer. Cancer Cell 2006; 9(5):333-339.
47. Storey J, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100:9440-9445.
48. de Kok J, Roelofs R, Giesendorf B, Pennings J, Waas E, Feuth T, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005; 85:154-159.
49. Camp R, Dolled-Filhart M, Rimm D. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res 2004; 10(Nov1):7252-7259.
50. Dowsett M, Hanna W, Kockx M, Pennault-Llorca F, Ruschoff J, Gutjahr T, et al. Standardization of HER2 testing: results of an international proficiency testing ring study. Mod Pathol 2007; 20:584-591.
51. Matkowskyj K, Cox R, Jensen R, Benya R. Quantitative Immunohistochemistry by Measuring Cumulative Signal Strength Accurately Measures Receptor Number. J Histochem Cytochem 2003;51(2):205-214.
52. Hu J-J, Ambrus A, Fossum T, Miller M, Humphrey J, Wilson E. Time Courses of Growth and Remodeling of Porcine Aortic Media During Hypertension: A Quantitative Immunohistochemical Examination. J Histochem Cytochem 2008;56(4):359-370.
53. Wester K, Wahlund E, Sundstrom C, Ranefall P, bengtsson E, Russell P, et al. Parrafin Section Storage and Immunohistochemistry. Appl Immunohistochem Mol Morphol 2000;8(1):61-70.
54. Halushka M, Cornish T, Lu J, Selvin S, Selvin E. Creation, validation, and quantitative analysis of protein expression in vascular tissue microarrays. Cardiovasc Pathol 2009: doi: 10.1016/j.carpath.2008.12.007.
55. Halushka M, Selvin E, Macgregor A, Cornish T. The use of vascular tissue microarrays for measurement of advanced glycation end products. J Histochem Cytochem 2009: DOI: 10.1369/jhc.2009.953273.
56. Cregger M, Berger A, Rimm D. Immunohistochemistry and Quantitative Analysis of Protein Expression. Arch Pathol Lab Med 2006; 130:1026-1030.
57. Paizis M, Engelhardt J, Siklos L. Quantitative assessment of relative changes of immunohistochemical staining by light microscopy in specified anatomical regions. J Microsc 2009; 234(1):103-112.
58. Kayser K, Gorter J, Metze K, Goldmann T, Vollmer E, Mireskandari M, et al. How to measure image quality in tissue-based diagnosis (diagnostic surgical pathology). BMC Diagn Pathol 2008;3(Supl 1):S11.
59. van der Loos C. Multiple Immunoenzyme Staining: Methods and Visualizations for the Observation With Spectral Imaging. J Histochem Cytochem 2008; 56(4):313-328.
60. Ruifrok A, Johnson D. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23:291-299.
61. Ruifrok A, Katz R, Johnson D. Comparison of Quantification of Histochemical Staining By Hue-Saturation-Intensity (HSI) Transformation and Color-Deconvolution. Appl Immunohistochem Mol Morphol 2003; 11(1):85-91.
62. Brey E, Lalani Z, Johnston C, Wong M, McIntire L, Duke P, et al. Automated Selection of DABlabeled Tissue for Immunohistochemical Quantification. J Histochem Cytochem 2003; 51(5):575-584.
63. Pham N-A, Morrison A, Schwock J, Aviel-Ronen S, Iakolev V, Tsao M-S, et al. Quantitative image analysis of immunohistochemical stains using a CMYK color model. BMC Diagn Pathol 2007; 2:8.
64. Charpin C, Secq V, Giusiano S, Carpenter S, Andrac L, Lavaut M-N, et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009; 124:2124-2134.
65. Su A, Welsh J, Sapinoso L, Kern S, Dimitrov P, Lapp H, et al. Molecular classification of Human Carcinomas by Use of Gene Expression Signatures. Cancer Res 2001; 61:7388-7393.
66. Glinsky GV, Higashiyama T, Glinski AB. Classification of Human Breast Cancer Using Gene Expression Profiling as a Component of the Survival Predictor Algorithm. Clin Cancer Res 2004; 10:2272-2283.
67. Rhodes D, Chinnayan A. Integrative analysis of the cancer transcriptome. Nat Genet Supplement 2005; 37:S31-37.
68. Pinkel D, Albertson D. Array comparative genomic hybridization and its applications in cancer. Nature Genetics Supplement 2005; 37:S11-17.
69. Talbot S, Estilo C, Maghami E, Sarkaria I, Pham D, O-Charoenrat P, et al. Gene Expression Profiling Allows Distinction between Primary and Metastatic Squamous Cell Carcinomas in the Lung. Cancer Research 2005; 65(8):3063-3071.
70. Nishizuka S, Chen S-T, Gwadry F, Alexander J, Major S, Scher U, et al. Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling. Cancer Research 2003; 63(Sep 1):5243-5250.
71. Veradhachary G, Talantov D, Raber M, Meng C, Hess K, Jatkoe T, et al. Molecular Profiling of Carcinoma of Unknown Primary and Correlation with Clinical Evaluation. J Clin Oncology 2008; 26(27):4442-4448.